Emin KAYA, Mehmet Ali ERKURT, Irfan KUKU, Ahmet SARICI, Ilhami BERBER, Soykan BİÇİM, Mustafa ÖZGÜL

Successful treatment with convalescent plasma in Covid-19 disease in relaps/refractory multiple myeloma

The Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus detected in the Wuhan Province of the People's Republic of China caused a pandemic in a very short time all over the world. Convalescent plasma (CP) therapy is a passive antibody therapy that has been shown to be effective in epidemic periods. CP therapy has been of interest in the treatment of infection with no vaccine or specific treatment, such as the Sars-CoV-2 infection that causes COVID-19. We aimed to report our CP experience in Sars-Cov-2 infection in our relapsed / refractory Multiple myeloma (MM) patient.

PDF

___

1. Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2020;72:340-50.
2. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34:1-9.
3. Dhakal B, Patel S, Girnius S, Bet al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 2020;34:1-10.
4. Rodriguez-Morales AJ, Cardona-Ospina JA, GutiérrezOcampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and metaanalysis. Travel Med Infect Dis 2020;34:101623.
5. Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020;7:e671-e8.
6. O'Malley JJ, Hartman FW. Treatment of influenzal pneumonia with plasma of convalescent patients. JAMA 1919;72:34-7.
7. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
8. Bahcecioglu OF, Gok S, Arisoy S. Stem Cell Therapy and Medications That Could Be Alternative to the Current COVID-19 Management. J Lit Pharm Sci 2020;9:319-28.
9. Senefeld J, Klassen SA, Ford SK, et al. Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review. medRxiv 2020.
10. Alsharidah S, Ayed M, Ameen RM, et al. COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study. Int J Infect Dis 2020;103:439- 46.
11. ah Yoon H, Bartash R, Gendlina I, et al. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. medRxiv 2020.
12. Libster R, Marc GP, Wappner D, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv 2020.
13. Jamir I, Lohia P, Pande RK, et al. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg 2020;24:526.
14. London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. J Clin Immunol 2021;41:356-61.
15. Ahmad A, Salsabil M, Oliver T. Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients. medRxiv 2020.
16. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19. Blood 2020;136:2290-5.
17. Moore JL, Ganapathiraju PV, Kurtz CP, et al. A 63-YearOld Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep 2020;21:e927812.
18. Baang JH, Smith C, Mirabelli C, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis 2021;223:23-7.
19. Luetkens T, Metcalf R, Planelles V, et al. Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv 2020;4:4864-8.
20. Van Damme KF, Van Roy N, De Leeuw E, et al. Convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19-a first case report. Front Immunol 2020;11:3041.